Key Stats for UnitedHealth Stock
- Current Price: $323.48
- TIKR Target Price (Mid): ~$575
- Street Consensus Target: ~$360
- Potential Total Return: ~78%
- Annualized IRR: ~13% / year
- Earnings Reaction: +7.93% (April 21, 2026)
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
For sixteen months, UnitedHealth (UNH) had been one of the most punishing large-cap stocks in the market. Shares fell roughly 34% in 2025 and another 18% into early 2026, as a medical cost surge, a DOJ criminal investigation, and a Medicare reimbursement squeeze erased over $200 billion in market value.
Bulls argued the 2025 repricing actions were finally working. Bears said the DOJ probe and contracting membership made the recovery too fragile to trust.
This morning, UnitedHealth reported Q1 2026 adjusted EPS of $7.23, beating the $6.65 Wall Street estimate by $0.58, with revenue of $111.72 billion also ahead of consensus. The company raised its full-year 2026 adjusted EPS outlook to more than $18.25 per share, up from the prior guidance of more than $17.75. The stock jumped 7.93% on the session.
The number that mattered most was not the EPS beat. UnitedHealth’s medical benefit ratio (the share of premium revenue paid out as medical claims) came in at 83.9% for the quarter, better than analysts expected and improved from 84.8% in Q1 2025.
CFO Wayne DeVeydt said on the call that the improvement reflected “pricing discipline, strong medical cost management and favorable reserve development,” with $8.9 billion in operating cash flows for the quarter at 1.4x net income.
All four segments beat internal plan expectations.
Chairman and CEO Stephen Hemsley, who returned to lead the company after Andrew Witty’s abrupt exit in May 2025, was direct: “This management team believes we are a long way from performing to our full potential, and we’re committed to getting to that potential quarter after quarter.”
See historical and forward estimates for UnitedHealth stock (It’s free!) >>>
Is UnitedHealth Undervalued Today?
At $323.48, UNH trades at around 18x NTM (next twelve months) earnings and around 13x NTM EV/EBITDA, per TIKR data. The Street’s mean price target across 26 analysts is $360.46, with 15 Buys, 7 Outperforms, 5 Holds, and 1 Sell among the 29 analyst recommendations tracked by TIKR. Jefferies raised its price target to $373 ahead of today’s results, while Morgan Stanley elevated UNH to a Top Pick with a $375 target.
Both cited potential for a sustainable margin recovery.
Today’s results provided concrete proof on two fronts. UnitedHealthcare CEO Tim Noel confirmed Medicare Advantage trends are tracking the pricing assumptions management built into 2026, with “modest favorability in government programs.”
Given that UNH missed its own guidance four straight quarters in 2025, in-line performance is a meaningful step forward.
At OptumHealth (the value-based care segment that was the biggest drag on earnings last year), operational improvements are showing up in hard numbers. Patrick Conway, President of Optum, said clinical reviews in the West region rose more than 50% since last quarter, driving a roughly 35% drop in skilled nursing facility admissions in the first month compared to last year. Patient-facing hours rose 12% year-over-year. OptumRx onboarded more than 800 new clients while cutting contact center volume 25% through AI tools. Management reaffirmed OptumHealth’s long-term target margins of 6% to 8%.
The bear case is not resolved. The DOJ’s criminal and civil investigations into UnitedHealth’s Medicare billing practices remain active, focused on whether the company inflated patient diagnoses to trigger higher government reimbursements.
No charges have been filed, and no resolution timeline has been given.
Any adverse outcome affecting Optum’s physician structure would directly undermine the integrated care model that the recovery thesis depends on. UnitedHealthcare also expects total membership to fall by approximately 1.3 million in 2026 as the company exits underpriced markets, and Medicaid margins are expected to remain negative through 2026.
The results came just weeks after the Trump administration finalized a 2027 Medicare Advantage payment rate increase that was far larger than the initial proposal, a meaningful tailwind for the sector.
That shift, combined with today’s MCR print, moves the market’s question from “how deep is the hole” to “how fast can they climb out.” The stock also pays a dividend yield of 2.7%, adding to the return case while the margin recovery plays out.
See how UnitedHealth performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $323.48
- TIKR Target Price (Mid): ~$575
- Potential Total Return: ~78%
- Annualized IRR: ~13% / year
See analysts’ growth forecasts and price targets for UnitedHealth stock (It’s free!) >>>
The TIKR mid-case uses around 4% revenue CAGR through 2030, well below UNH’s 10-year historical figure of 11%, and a net income margin of around 5%, below the 6% to 6.5% the company averaged before 2025. The model is not pricing in a full return to prior performance levels.
Two revenue drivers support the case. First, UnitedHealthcare’s repricing across commercial and Medicare segments is tracking as intended in 2026. Second, OptumRx’s 800-plus new client relationships from 2025 will scale through revenue as the year progresses. The margin driver is an AI investment. UNH is committing nearly $1.5 billion to AI initiatives in 2026, with Optum CTO Sandeep Dadlani saying on today’s call that the company expects a 2:1 return on those programs over the next several years, with many paying back within 12 to 18 months. The primary risk is the DOJ investigation. Adverse outcomes affecting Optum’s physician structure would make the margin recovery significantly harder to achieve.
Free cash flow consensus projects recovery from the $16 billion 2025 level toward $19 billion by 2028, per TIKR estimates. The scenario analysis requires neither a full recovery to historical margins nor a clean legal resolution, only steady execution against a conservative baseline.
Conclusion
Watch the medical benefit ratio at Q2 2026 earnings. Management guided first-half MCR more than 250 basis points below the full-year midpoint, so the second half is the real test. A second-half MCR above 87% signals the repricing is not holding; a print in line with guidance validates the path toward the TIKR mid-case. UNH at $323 is a bet that the largest private insurer in the U.S. can execute a margin recovery under two open federal investigations. Today’s Q1 results are the strongest evidence yet that the execution is real.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in UnitedHealth?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up UnitedHealth, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track UnitedHealth alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze UnitedHealth on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
